Rick Lifsitz, MBA; Larry Blandford, PharmD—Column Editor

In the June 2016 article, “Could the Lack of an Efficient and Affordable Diagnostic Pathway Limit Market Access for New Alzheimer’s Treatments?”1 the author and column editor would like to clarify several points. 
Authors take a look at how improved diagnostic testing can lead to better care for patients with Alzheimer's disease.